Publications by authors named "P J Daeninck"
Background: Since 2001, Canadians have been able to obtain cannabis for medical purposes, initially through the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Cannabis Act (Bill C-45) came into force on October 17, 2018, replacing the ACMPR. The Cannabis Act enables Canadians to possess cannabis purchased from a licensed retailer without authorization for either medical or nonmedical purposes.
View Article and Find Full Text PDFPurpose: Pancreatic cancer is a lethal disease. Many patients experience a heavy burden of cancer-associated symptoms and poor quality of life (QOL). Early palliative care alongside standard oncologic care results in improved QOL and survival in some cancer types.
View Article and Find Full Text PDFArticle Synopsis
- One in five people worldwide suffer from chronic pain, often linked with sleep issues, anxiety, depression, and substance use disorders, leading to increased interest in cannabinoid-based medicines (CBM) for management.
- Health care providers lack sufficient information regarding the risks, benefits, and proper use of CBM, prompting the creation of clinical practice guidelines to assist in its application for chronic pain and related conditions.
- A systematic review of 70 studies indicated moderate evidence supporting the use of CBM in chronic pain management and its effectiveness in addressing comorbidities, while highlighting the necessity for patient education on risks and collaborative decision-making regarding treatment options.
Aims: Opioid misuse and overuse have contributed to a widespread overdose crisis and many patients and physicians are considering medical cannabis to support opioid tapering and chronic pain control. Using a five-step modified Delphi process, we aimed to develop consensus-based recommendations on: 1) when and how to safely initiate and titrate cannabinoids in the presence of opioids, 2) when and how to safely taper opioids in the presence of cannabinoids and 3) how to monitor patients and evaluate outcomes when treating with opioids and cannabinoids.
Results: In patients with chronic pain taking opioids not reaching treatment goals, there was consensus that cannabinoids may be considered for patients experiencing or displaying opioid-related complications, despite psychological or physical interventions.
Introduction: Chronic pain and co-occurring disorders, such as sleep disorders, anxiety, depression, post-traumatic stress disorder and substance use disorders, are among the most common conditions for which cannabis and cannabinoid-based products derived from the cannabis plant (CBP) are used for therapeutic purposes. However, healthcare providers report that they lack sufficient information on the risks, benefits and appropriate use of cannabis and CBP derived from the cannabis plant for therapeutic purposes.
Methods And Analysis: We will conduct a systematic review of studies investigating the use of cannabis and CBP derived from the cannabis plant for the treatment of chronic pain and co-occurring conditions.